Share on StockTwits

Genomic Health (NASDAQ:GHDX) will be issuing its Q214 quarterly earnings data on Tuesday, August 5th. Analysts expect the company to announce earnings of ($0.26) per share and revenue of $69.04 million for the quarter.

Genomic Health (NASDAQ:GHDX) last announced its earnings results on Tuesday, May 6th. The company reported ($0.24) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.18) by $0.06. The company had revenue of $67.00 million for the quarter, compared to the consensus estimate of $68.47 million. During the same quarter last year, the company posted ($0.03) earnings per share. Genomic Health’s revenue was up 6.2% compared to the same quarter last year. On average, analysts expect Genomic Health to post $-0.91 EPS for the current fiscal year and $-0.53 EPS for the next fiscal year.

Genomic Health (NASDAQ:GHDX) remained flat at $25.54 during during mid-day trading trading on Monday. The stock had a trading volume of 22,202 shares. Genomic Health has a one year low of $23.90 and a one year high of $37.24. The stock has a 50-day moving average of $26.98 and a 200-day moving average of $27.42. The company’s market cap is $797.9 million.

A number of research firms have recently commented on GHDX. Analysts at Zacks reiterated a “neutral” rating on shares of Genomic Health in a research note on Thursday, July 3rd. They now have a $29.00 price target on the stock. Analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Genomic Health in a research note on Wednesday, May 7th. They now have a $28.00 price target on the stock, down previously from $29.00. Four investment analysts have rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $28.57.

Genomic Health, Inc (NASDAQ:GHDX) is a molecular diagnostics company focused on the global development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.